Business
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
- LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells - LP-284 exhibited potency in lymphoma, multiple myeloma, and leukemia cell
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells\n - LP-284 exhibited potency in lymphoma, multiple myeloma, and leukemia cell lines\n - Data supports potential development in important new rare blood cancer indications\n\n\nDALLAS, Dec. 14, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma presented positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting, which was held in-person and virtually from December 11 – 14, 2021. This poster presentation can be viewed on Lantern Pharma's website at: https://www.lanternpharma.com/about/publications.LP-284 is a fully synthetic molecule belonging to the new generation of acylfulvenes, a family of naturally derived anti-cancer drug candidates. LP-284 is the stereoisomer (enantiomer) of LP-184 and has the potential for development as monotherapy and also as a synergistic agent in combination with other drugs. LP-284 is currently being evaluated for activity in a wide spectrum of hematological cancers. Earlier this year, Lantern filed multi-national patent applications directed to both the composition and manufacture of LP-284.\n\nThe study demonstrated LP-284's broad in vitro anti-tumor activity in lymphoma, multiple myeloma, and leukemia cells. Notably, the enantiomer pair, LP-184 and LP-284, exhibit distinct patterns of anti-tumor activities. As a result, the novel enantiomer LP-284 may provide a targeted therapy option for hematologic cancers with compromised DNA repair, supporting further targeted development plans for LP-284.\n\"Approximately every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma or myeloma and approximately every 9 minutes someone in the U.S. dies from a blood cancer1,\" commented Panna Sharma, CEO and President of Lantern Pharma Inc. \"There is an urgent need to develop new, targeted therapies; however, the current industry approach is time consuming and expensive. This latest data provides further validation of Lantern's RADR® platform, which leverages A.I. and machine learning with the aim of dramatically...